Understanding Alterations in an Early Experimental Glaucoma Model
Principal Investigator
Hongli Yang, PhD
Good Samaritan Foundation, Legacy Health System
Portland, OR, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$199,992
Active Dates
July 01, 2022 - June 30, 2025
Grant ID
G2022008S
Co-Principal Investigator(s)
Goals
Our goal is to identify the cellular and molecular alterations underlying optical coherence tomography early structural change in a non-human primate experimental glaucoma (EG) model.
Summary
In Aim 1, we will compare protein expression changes within 30-degree optical coherence tomography (OCT) optic nerve head (ONH) sectors demonstrating 30% nerve fiber thickness loss in glaucoma vs control eyes. In Aim 2, will colocalize immunohistochemistry section to a virtual OCT B-scan generated from high-resolution isotropic OCT ONH data set. We will compare the longitudinal OCT deep ONH structural and reflectance intensity changes from baseline to protein expression alterations at equivalent locations in the EG versus control eyes.
Unique and Innovative
Our strategies to colocalize immunostained sections to nerve fiber layer loss detected by optical coherence tomography (OCT) and colocalize these sections to OCT structural and intensity change within a best-matched virtual OCT B-scan are innovative. Previous studies have looked at global measures by immunohistochemistry that do not account for the focal nature of glaucomatous damage. By colocalization, we aim to examine changes in sectors that have not yet shown significant OCT thinning, allowing us to investigate cellular alterations across a range of disease stages within the same eye.
Foreseeable Benefits
The translational importance of this work will be two-fold. First, it will provide strong support and perhaps mechanistic direction for the treatment of early OCT-detected structural change in human eyes at risk for developing glaucoma such as those with suspicious optic discs or ocular hypertension. Second, it will advance our understanding of early glaucoma pathophysiologic mechanisms and in so doing foster ONH-targeted neuroprotective interventions designed to stabilize or reverse the neuropathy of glaucoma early in its course.
Grants
Related Grants
National Glaucoma Research
Understanding How Variants in LOXL1 Affect Pseudoexfoliation Glaucoma Risk
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Hannah Youngblood, PhD
Understanding How Variants in LOXL1 Affect Pseudoexfoliation Glaucoma Risk
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Hannah Youngblood, PhD
National Glaucoma Research
Defining the Role of a New Protein Target in Fluid Buildup in Glaucoma
Active Dates
July 01, 2023 - June 30, 2025
Principal Investigator
Rupalatha Maddala, PhD
Defining the Role of a New Protein Target in Fluid Buildup in Glaucoma
Active Dates
July 01, 2023 - June 30, 2025
Principal Investigator
Rupalatha Maddala, PhD
National Glaucoma Research
A Possible Connection Between Glaucoma and Alzheimer's Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Nick Marsh-Armstrong, PhD
A Possible Connection Between Glaucoma and Alzheimer's Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Nick Marsh-Armstrong, PhD